UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients

Nephrology (Carlton, Vic.), 2015-08, Vol.20 (8), p.531-538

2015

Volltextzugriff (PDF)

Quality of life in Japanese patients with type 1 diabetes and end-stage renal disease undergoing simultaneous pancreas and kidney transplantation

Diabetology international, 2017-08, Vol.8 (3), p.268-274

2017

Volltextzugriff (PDF)

Novel, Potent, and Selective Phosphodiesterase 5 Inhibitors: Synthesis and Biological Activities of a Series of 4-Aryl-1-isoquinolinone Derivatives

Journal of medicinal chemistry, 2001-06, Vol.44 (13), p.2204-2218

2001

Volltextzugriff (PDF)

Acute and Chronic Effects of T-1032, a Novel Selective Phosphodiesterase Type 5 Inhibitor, on Monocrotaline-Induced Pulmonary Hypertension in Rats

Biological and Pharmaceutical Bulletin, 2002, Vol.25(11), pp.1422-1426

2002

Volltextzugriff (PDF)

Non-linear association between ankle-brachial pressure index and prevalence of silent cerebral infarction in Japanese patients with type 2 diabetes

Atherosclerosis, 2012-06, Vol.222 (2), p.490-494

2012

Volltextzugriff (PDF)

Inhibitory Effects of TA-993 and Its Metabolite MB3 on Platelet Activation Induced by Collagen and U-46619 in Human Platelets

Biological and Pharmaceutical Bulletin, 2001, Vol.24(5), pp.501-504

2001

Volltextzugriff (PDF)

Obesity as an effect modifier of the association between leptin and diabetic kidney disease

Journal of diabetes investigation, 2014-03, Vol.5 (2), p.213-220

2014

Volltextzugriff (PDF)

Antiplatelet mechanisms of TA-993 and its metabolite MB3 in ADP-induced platelet aggregation

European journal of pharmacology, 2000-07, Vol.399 (2), p.91-96

2000

Volltextzugriff (PDF)

Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta

European journal of pharmacology, 2002-04, Vol.440 (1), p.45-52

2002

Volltextzugriff (PDF)

1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors

Bioorganic & medicinal chemistry letters, 2003-07, Vol.13 (14), p.2341-2345

2003

Volltextzugriff (PDF)

Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum

European journal of pharmacology, 2001-01, Vol.411 (1-2), p.161-168

2001

Volltextzugriff (PDF)

Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor

European journal of pharmacology, 2002-12, Vol.456 (1), p.91-98

2002

Volltextzugriff (PDF)

T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters

European journal of pharmacology, 2002-05, Vol.443 (1), p.179-184

2002

Volltextzugriff (PDF)

Inhibition of contractions of vascular smooth muscles by TEA and 4-aminopyridine

Japanese Journal of Pharmacology, 1994, Vol.64 (suppl.1), p.242-242

1994

Volltextzugriff (PDF)

Modification by cyclopiazonic acid and ryanodine of depolarization-induced constriction in rat mesenteric artery

European journal of pharmacology, 1994-01, Vol.251 (2), p.307-310

1994

Volltextzugriff (PDF)

T-1032, a specific phosphodiesterase type 5 inhibitor, improves the survival rate in cardiomyopathic hamsters with heart failure

Japanese Journal of Pharmacology, 2001, Vol.85 (suppl.1), p.102-102

2001

Volltextzugriff (PDF)

P-205 - Inhibition of contractions of vascular smooth muscles by TEA and 4-aminopyridine

Japanese journal of pharmacology, 1994, Vol.64, p.242-242

1994

Volltextzugriff (PDF)

Pharmacological profile of T-0156, a newly synthetized phosphodiesterase type 5 inhibitor, in anesthetized dogs

Japanese Journal of Pharmacology, 2001, Vol.85 (suppl.2), p.282-282

2001

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(18)

Sprache

Englisch
(16)
Japanisch
(7)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients

Quality of life in Japanese patients with type 1 diabetes and end-stage renal disease undergoing simultaneous pancreas and kidney transplantation

Novel, Potent, and Selective Phosphodiesterase 5 Inhibitors: Synthesis and Biological Activities of a Series of 4-Aryl-1-isoquinolinone Derivatives

Acute and Chronic Effects of T-1032, a Novel Selective Phosphodiesterase Type 5 Inhibitor, on Monocrotaline-Induced Pulmonary Hypertension in Rats

Non-linear association between ankle-brachial pressure index and prevalence of silent cerebral infarction in Japanese patients with type 2 diabetes

Inhibitory Effects of TA-993 and Its Metabolite MB3 on Platelet Activation Induced by Collagen and U-46619 in Human Platelets

Obesity as an effect modifier of the association between leptin and diabetic kidney disease

Antiplatelet mechanisms of TA-993 and its metabolite MB3 in ADP-induced platelet aggregation

Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta

1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors

Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum

Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor

T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters

Inhibition of contractions of vascular smooth muscles by TEA and 4-aminopyridine

Modification by cyclopiazonic acid and ryanodine of depolarization-induced constriction in rat mesenteric artery

T-1032, a specific phosphodiesterase type 5 inhibitor, improves the survival rate in cardiomyopathic hamsters with heart failure

P-205 - Inhibition of contractions of vascular smooth muscles by TEA and 4-aminopyridine

Pharmacological profile of T-0156, a newly synthetized phosphodiesterase type 5 inhibitor, in anesthetized dogs

Suchergebnisse filtern